Allogeneic hematopoietic SCT (HSCT) from an HLA-identical sibling donor is the recommended upfront therapeutic option for young patients with SAA. The outcome of allogeneic sibling HSCT has remarkably improved during the last decade as a function of improvement in transplantation supportive care. However, there is still much debate concerning the upper age limit for sibling HSCT in SAA, particularly in patients who are refractory to at least one immunosuppressive course. Recent studies suggest that fludarabine-based conditioning may improve HSCT outcome in older patients with SAA. This review discusses available data about the use of fludarabine-based conditioning in transplantation of older patients with SAA. More definitive conclusions are needed from larger studies before the wide adoption of fludarabine-based conditioning as an alternative to the standard CY and ATG-based conditioning. (2013) 48, 196-197; doi:10.1038/bmt.2012.251; published online 10 December 2012
HLA-IDENTICAL SIBLING HSCT IN OLDER PATIENTS
Allogeneic hematopoietic SCT (HSCT) from an HLA-identical sibling donor is the first line treatment of choice for newly diagnosed patients with severe acquired idiopathic aplastic anemia (SAA) younger than 40 years.
However, for older patients X40 years, the decision whether to treat with immunosuppressive therapy (IST), namely antithymocyte globulin (ATG) and cyclosporine, or to transplant upfront from an HLA-identical sibling donor remains a key question. Two large studies from Seattle 1 and the European Group for Blood and Marrow Transplantation (EBMT) SAA Working Party 2 that examined survival by age group did not show an advantage for either HSCT or IST in older patients. This was notably related to a lower long-term survival after HSCT for older patients, that is, 440 years in the Seattle cohort 1 and 420 years in the European study. 2 The negative impact of older age at transplant has been confirmed in several other studies. [3] [4] [5] A recently published large study from the CIBMTR performed on 1307 patients analyzed the impact of age on outcome after sibling donor HSCT for SAA. 6 Patients older than 40 years were more likely to (i) have had immunosuppressive therapy before HSCT, (ii) have a poor performance status, (iii) have an interval from diagnosis to HSCT of43 months and (iv) have received a PBSC graft. The mortality risk was higher in patients over 40 years than in patients 20-40 years (P ¼ 0.008) and patients less than 20 years old (Po0.0001).
IMPACT OF CONDITIONING REGIMEN MODIFICATIONS IN OLDER PATIENTS
The standard conditioning regimen for HLA identical sibling HSCT relies on CY, with or without ATG. In order to improve survival in patients older than 40 years, the use of less cytotoxic but more immunosuppressive regimens including lowered dose of CY (below the standard dose of 200 mg/kg) in combination with ATG, while adding fludarabine, might be an option to explore with the aim of reducing transplant-related mortality. Notably, there are concerns about cardiac toxicity of CY at the standard dose of 200 mg/kg in older patients. In a recent series of 23 SAA patients aged 43-68 years who received CY at 200 mg/kg, 7 fluid overload was reported in 6 patients, which contributed to cause of death in 4. Fludarabine-based regimens have been explored in various non-malignant diseases without conferring a significant survival advantage when compared with conventional myeloablative regimens. 8 In patients with SAA specifically, several noncomparative studies have reported encouraging results in the setting of HLA-matched related HSCT. [9] [10] [11] [12] [13] A recent report from the EBMT SAA working party retrospectively analyzed 30 patients older than 30 years receiving reduced-intensity conditioning HSCT (using fludarabine 30 mg/m 2 Â 4, CY 300 mg/m 2 Â 4 and most with ATG, namely a FCA regimen) and compared their outcome with a control group receiving the standard regimen (CY þ / À ATG) over the same study period (1998-2007).
14 Recipients of fludarabine-based conditioning had a higher probability of ageadjusted overall survival than the control group (P ¼ 0.04). This was hypothesized to be due to a reduced incidence of graft failure in patients receiving fludarabine (0% versus 11%, P ¼ 0.09), whereas no difference was observed in the incidence of GVHD. This study suggested that fludarabine-based conditioning regimens may reduce the negative impact of age in older patients with SAA receiving sibling HSCT.
In a recently published multicenter retrospective study, 15 a modification to the above regimen, using alemtuzumab (Campath 1-H) instead of ATG (namely a fludarabine þ CY þ Campath ¼ FCC regimen) has been used in 50 patients transplanted from matched sibling (21) or unrelated (29) donors. GVHD prophylaxis relied on cyclosporine alone without MTX. The median age of the patients was 35 years (range 8-62). OS at 2 years was 95±5% for matched sibling donors and 83% for unrelated donors HSCT (P ¼ 0.34). Cumulative incidence of graft failure was 9.5 for matched sibling donors and 14.5% for unrelated donors HSCT. Full donor chimerism in unfractionated peripheral blood was 42%; no patient achieved CD3 full donor chimerism. Acute GVHD was observed in only 13.5% patients (all grade I-II) and only 2 patients (4%) developed chronic GVHD. A low incidence of viral infections was observed in this study.
An important prognostic factor for survival was the comorbidity index, as assessed by the Sorror score. A total score of X2 indicated a worse outcome with OS of only 42%. Conversely, favorable OS of 71% was noted in patients older than 50 years of age with low comorbidity indexes. This incites to consider co-morbidities together with age (may be rather than age?) for the careful selection of patients before HSCT. Overall, the low toxicity of FCC, as well as low risk of GVHD and infections, makes this combination an attractive alternative preparative regimen for HSCT in older patients with SAA. Similar improved results using RIC-HSCT have also been reported recently in older patients with myelodysplastic syndromes. [16] [17] [18] Due to this improved results, older age may no more further impact on outcome after HSCT 18 .
CONCLUSION
There is still much debate concerning the upper age limit for sibling HSCT in SAA. In patients who are refractory to at least one IST course, recent results suggest that a fludarabine-based conditioning (FCA or FCC) may improve results in older patients. However, more definitive data are needed from larger studies before the wide adoption of fludarabine-based conditioning as an alternative to the standard CY and ATG conditioning.
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